Skip to search formSkip to main contentSkip to account menu

CN 3123

Known as: CN-3123 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Sulfamoxole / Trimethoprim

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1977
1977
[Antibacterial therapy of urinary tract infections. Results of a clinical trial with the combination sulfamoxol/Trimethoprim (= CN 3123) (author's transl)].
In the present paper, the use of the combination preparation sulfamoxol/trimethoprim (CN 3123, Nevin [Grünenthal], Supristol… 
1976
1976
[The management of urinary tract infections with CN-3123. Experience with gynecologic patients and women in childbirth].
1976
1976
[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123)/Sixth communication: Results of compatibility of CN 3123 (author's transl)].
1. During the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy… 
1976
1976
[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123). 2. Results of a multicenter clinical trial of CN 3123 in infections of the kidneys and urinary tract].
During the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl… 
Review
1976
Review
1976
[Toxicological investigations of the combination sulfamoxole/trimethoprim, a new broad-spectrum chemotherapeutic (author's transl)].
The chemotherapeutically effective 5:1 combination N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3… 
1976
1976
[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123). 1st communication. Efficacy activity spectrum--resistance in therapy (author's transl)].
The clinical trial of the combination N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)